Drug Profile
Lanicemine -Biohaven Pharmaceuticals
Alternative Names: ARL 15896; ARL 15896AR; ARR 15896; ARR 15896AR; BHV-5500; FPL 15896; FPL 15896ARLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astra Arcus USA
- Developer Astra Arcus USA; Biohaven Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pain
- Discontinued CNS disorders; Epilepsy; Stroke
Most Recent Events
- 09 Nov 2022 Early research in Pain in USA (unspecified route)
- 03 Oct 2022 Biohaven Pharmaceuticals has been acquired by Pfizer
- 31 May 2017 Baylor College of Medicine and National Institute of Mental Health plan a phase I trial for Depression and Post traumatic stress disorders (NCT03166501)